Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 139 participants.

Also called NCT02996435

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 139 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02996435
Other papers using this trial's data
  • Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial American heart journal, 2021-07 DOI, PubMed 33676886

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02996435. Randomized; no masking; primary purpose other. Start 2016-12-21 (actual); primary completion 2018-03-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
Intervention (Behavioral)
Mobile Application Intervention
Intervention (Other)
No Intervention
Lead sponsor
Janssen Scientific Affairs, LLC (class: industry)

Record details

Record id
cardio:ct-nct02996435
Content hash
66cb6064d1f08ddceba7b3c412130b35883e95fca606f1c066d1c3617ba56fa0